Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 13,479 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: cGVHD Clear all
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection

NCT01590654
View directory record Official record
Conditions
Hepatitis B
Interventions
Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
Phoenix, Arizona • Indianapolis, Indiana • New Orleans, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 27, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

NCT03615105
View directory record Official record
Conditions
Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide, Busulfan, Fludarabine, Melphalan, Clofarabine, HPC(A) stem cell allograft, Rituximab, Rabbit antithymocyte globulin
Radiation · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

NCT04681105
View directory record Official record
Conditions
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Interventions
Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 27, 2026, 5:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

NCT04657094
View directory record Official record
Conditions
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Acalabrutinib
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

NCT01629082
View directory record Official record
Conditions
Myeldysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia, Bone Marrow Diseases, Neutropenia, Acute Myeloid Leukemia (AML)
Interventions
Clofarabine, Lenalidomide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 27, 2026, 5:43 AM EDT
Active, not recruiting Not applicable Interventional

Mindfulness-Based Stress Reduction for Emotional Recovery After Stroke

NCT07491861
View directory record Official record
Conditions
Chronic Stroke Patients
Interventions
Mindfulness-Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer

NCT00003294
View directory record Official record
Conditions
Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 27, 2026, 5:43 AM EDT
Terminated Phase 3 Interventional Results available

The Everolimus-Transplant Exit Strategy Trial (E-TEST)

NCT01636466
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Everolimus
Drug
Lead sponsor
Ashtar Chami
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 27, 2026, 5:43 AM EDT
Not listed Phase 3 Interventional

Effect of Rozerem on the Perception of GERD Symptoms in Patients With Chronic Insomnia.

NCT01128582
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Chronic Insomnia
Interventions
Rozerem (ramelteon), placebo
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
Up to 82 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

NCT02684162
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Interventions
Donor Lymphocytes, Guadecitabine, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 27, 2026, 5:43 AM EDT
Withdrawn Phase 1 Interventional

Adipose-derived Stem Cells to Treat Chronic Wounds.

NCT05797688
View directory record Official record
Conditions
Wound of Skin
Interventions
The Celution System
Device
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00624286
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
118
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 105 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 27, 2026, 5:43 AM EDT
Active, not recruiting Not applicable Interventional

Clinical Utility of Neurophysiological Measurements of ECAP-controlled Closed-loop SCS to Guide Treatment of Chronic Pain

NCT06229470
View directory record Official record
Conditions
Chronic Pain
Interventions
Evoke Spinal Cord Stimulation (SCS) System
Device
Lead sponsor
Saluda Medical Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Lake Havasu City, Arizona • Camarillo, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

NCT01191762
View directory record Official record
Conditions
Hyperparathyroidism, Chronic Kidney Disease
Interventions
sevelamer carbonate, placebo
Drug
Lead sponsor
Kenneth R. Phelps, M.D.
Individual
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 2 Interventional Results available

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

NCT00683046
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia, Myeloproliferative Disorder, Anemia, Aplastic, Myelodysplastic Syndromes
Interventions
Fludarabine, Melphalan, Stem cells, Campath
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 2 Interventional

Virtual Environment Rehabilitation for Chronic Stroke

NCT01414686
View directory record Official record
Conditions
Stroke
Interventions
Commercially-Available Interactive Video Games
Other
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00685841
View directory record Official record
Conditions
COPD
Interventions
Arformoterol tartrate inhalation solution, Salmeterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
52
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Oct 27, 2026, 5:43 AM EDT
Terminated No phase listed Observational

Comparison of Chitodex Gel Vs NexFoam on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis

NCT05083741
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Chitogel, Nexfoam
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 5:43 AM EDT
Terminated Phase 2 Interventional

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

NCT00005641
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does a Mainstream Summer Camp Experience Improve Pediatric Kidney Patients' Physical Fitness and Self Concept?

NCT02803541
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
12 day mainstream summer camp experience
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Claryville, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Not applicable Interventional

Efficacy of Behavioral Insomnia Treatment for Chronic Migraine

NCT01314651
View directory record Official record
Conditions
Chronic Migraine, Insomnia
Interventions
Stimulus Control and Sleep Restriction, Lifestyle Modification
Behavioral
Lead sponsor
Daniel Riche
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 27, 2026, 5:43 AM EDT
Terminated Not applicable Interventional

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

NCT01241942
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Steen Solution™, Conventional Lung Transplant
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 3 Interventional

Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia

NCT00046683
View directory record Official record
Conditions
B Cell Chronic Lymphocytic Leukemia
Interventions
alemtuzumab
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Fort Myers, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Oct 27, 2026, 5:43 AM EDT
Completed Phase 1 Interventional

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

NCT00045266
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
25 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 27, 2026, 5:43 AM EDT